•
Sep 30, 2021

Zimmer Biomet Q3 2021 Earnings Report

Reported a decrease in net sales and updated 2021 financial guidance.

Key Takeaways

Zimmer Biomet reported third quarter net sales of $1.924 billion, a decrease of 0.3% from the prior year period. Diluted earnings per share were $0.69 for the third quarter, and adjusted diluted earnings per share were $1.81. The company updated its full-year 2021 financial guidance, reducing and narrowing its previous projected ranges for revenue growth, adjusted operating profit margin and adjusted diluted EPS.

Third quarter net sales of $1.924 billion decreased 0.3% and 0.8% on a constant currency basis.

Third quarter diluted earnings per share were $0.69; adjusted diluted earnings per share were $1.81.

Third quarter 2021 net sales increased 1.7% when compared to the pre-pandemic third quarter 2019, and increased 0.4% on a constant currency basis.

Company updates 2021 financial guidance, reducing and narrowing range for full year outlook

Total Revenue
$1.92B
Previous year: $1.93B
-0.3%
EPS
$1.81
Previous year: $1.81
+0.0%
Gross Profit
$1.34B
Previous year: $1.36B
-1.3%
Cash and Equivalents
$920M
Previous year: $967M
-4.9%
Free Cash Flow
$379M
Previous year: $287M
+31.9%
Total Assets
$24B
Previous year: $24B
-0.1%

Zimmer Biomet

Zimmer Biomet

Zimmer Biomet Revenue by Segment

Zimmer Biomet Revenue by Geographic Location

Forward Guidance

The Company is updating its full-year 2021 financial guidance to reduce and narrow its previous projected ranges for revenue growth, adjusted operating profit margin and adjusted diluted EPS.

Revenue & Expenses

Visualization of income flow from segment revenue to net income